| 1 |
33655416 | Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial. | 2021 Jun |
1 |
| 2 |
31959790 | Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia. | 2020 Jan 20 |
5 |
| 3 |
30948162 | Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. | 2019 Jul |
1 |
| 4 |
31779969 | Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach? | 2019 Dec |
5 |
| 5 |
29081694 | Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment. | 2017 Oct |
2 |
| 6 |
22338135 | [Clinical and cytogenetic features and their influencing factors of core binding factor acute myeloid leukemia]. | 2011 Oct |
1 |
| 7 |
20072158 | WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. | 2010 Jan 14 |
4 |
| 8 |
18932257 | Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. | 2008 Dec 1 |
5 |